Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Stephens Inc. AR

Stephens Inc. AR reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,210 shares of the medical research company’s stock after selling 1,253 shares during the quarter. Stephens Inc. AR’s holdings in Charles River Laboratories International were worth $777,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at about $32,000. Versant Capital Management Inc lifted its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at about $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

CRL stock opened at $153.20 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The stock’s 50 day moving average is $177.23 and its two-hundred day moving average is $191.71. The company has a market capitalization of $7.83 billion, a PE ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday, February 3rd. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).